Literature DB >> 7482422

High-dose intravenous immunoglobulin delays clearance of von Willebrand factor in acquired von Willebrand disease.

P J van Genderen, W Terpstra, J J Michiels, L Kapteijn, H H van Vliet.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7482422

Source DB:  PubMed          Journal:  Thromb Haemost        ISSN: 0340-6245            Impact factor:   5.249


× No keyword cloud information.
  6 in total

Review 1.  Intravenous immunoglobulin therapy for acquired coagulation inhibitors: a critical review.

Authors:  Koji Yamamoto; Junki Takamatsu; Hidehiko Saito
Journal:  Int J Hematol       Date:  2007-05       Impact factor: 2.490

2.  Acquired von Willebrand syndrome in a 10-year-old girl with acute lymphoblastic leukaemia.

Authors:  Isabel Dorn; Ulrich Budde; Michael C Frühwald; Monika Pöppelmann; Ulrike Nowak-Göttl
Journal:  BMJ Case Rep       Date:  2009-06-21

Review 3.  Acquired von Willebrand syndrome: its pathophysiology, laboratory features and management.

Authors:  Hiroshi Mohri
Journal:  J Thromb Thrombolysis       Date:  2003-06       Impact factor: 2.300

4.  Treatment of Acquired von Willebrand Syndrome and Prevention of Bleeding Postautologous Stem Cell Transplant during Severe Pancytopenia with IVIG.

Authors:  Behyar Zoghi; Paul Shaughnessy; Roger M Lyons; Richard Helmer; Carlos Bachier; C Frederick LeMaistre
Journal:  Case Rep Hematol       Date:  2015-04-02

5.  Perioperative intravenous immunoglobulin treatment in a patient with severe acquired von Willebrand syndrome: case report and review of the literature.

Authors:  Eva Jennes; Dorothee Guggenberger; Rainer Zotz; Lora Thompson; Tim H Brümmendorf; Steffen Koschmieder; Edgar Jost
Journal:  Clin Case Rep       Date:  2017-03-30

6.  Acquired von Willebrand syndrome in monoclonal gammopathy - A scoping review on hemostatic management.

Authors:  Mouhamed Yazan Abou-Ismail; George M Rodgers; Paul F Bray; Ming Y Lim
Journal:  Res Pract Thromb Haemost       Date:  2021-02-17
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.